Desipramine Hydrochloride

Insomnia, Bulimia Nervosa, Panic Disorder + 7 more

Treatment

1 FDA approval

20 Active Studies for Desipramine Hydrochloride

What is Desipramine Hydrochloride

Desipramine

The Generic name of this drug

Treatment Summary

Desipramine hydrochloride is an antidepressant drug belonging to a group of medications called tricyclic antidepressants. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps to improve mood. It is used to treat depression and other conditions such as neuropathic pain, agitation, and insomnia. Desipramine is generally considered to have fewer side effects than other tricyclic antidepressants, such as amitriptyline and clomipramine, but it can still cause sedation, blurred vision, dry mouth, constipation, and urinary retention.

Norpramin

is the brand name

image of different drug pills on a surface

Desipramine Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Norpramin

Desipramine

1964

122

Approved as Treatment by the FDA

Desipramine, also called Norpramin, is approved by the FDA for 1 uses including Depression .

Depression

Effectiveness

How Desipramine Hydrochloride Affects Patients

Desipramine is a type of antidepressant used to treat depression. It works by blocking the reuptake of noradrenaline and serotonin, two chemical messengers in the brain, and by making serotonin receptors more sensitive. It usually takes 2-4 weeks for the antidepressant effects to be felt, although some people may need up to 8 weeks. People with more severe depression may start feeling the effects sooner than those with mild depression.

How Desipramine Hydrochloride works in the body

Desipramine is a medication used to treat depression. It works by blocking the brain from reabsorbing norepinephrine and serotonin, which are chemicals that normally help regulate mood. Desipramine can also make serotonin receptors inside the brain more sensitive, which helps increase the amount of serotonin available. It also has a minor effect on other receptors in the brain, called muscarinic receptors. All of these effects together help to improve mood and reduce depression symptoms.

When to interrupt dosage

The advised dose of Desipramine Hydrochloride is contingent upon the established condition, including Irritable Bowel Syndrome (IBS), Neuropathic Pain and Chronic Pain. The measure of dosage is subject to the technique of delivery listed in the table beneath.

Condition

Dosage

Administration

Insomnia

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Irritable Bowel Syndrome

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Bulimia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Panic Disorder

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Depression

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Diabetic Neuropathy

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuralgia, Postherpetic

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Neuropathic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Anorexia Nervosa

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Chronic Pain

10.0 mg, , 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 150.0 mg

, Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Ophthalmic, Ophthalmic

Warnings

Desipramine Hydrochloride Contraindications

Condition

Risk Level

Notes

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Desipramine Hydrochloride.

Common Desipramine Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Desipramine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Desipramine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Desipramine is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Desipramine.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Desipramine.

Desipramine Hydrochloride Toxicity & Overdose Risk

Desipramine can be toxic at a dose of 290mg/kg in male mice and 320mg/kg in female rats. Side effects may include drowsiness, low blood pressure, blurred vision, dry mouth, constipation, and difficulty urinating. Higher doses can cause changes in blood pressure, heart rate, or electrical activity in the heart. Memory problems, confusion, or manic episodes may occur and withdrawal symptoms may include nausea, vomiting, abdominal pain, diarrhea, anxiety, insomnia, headache, and general discomfort.

image of a doctor in a lab doing drug, clinical research

Desipramine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Desipramine Hydrochloride?

Presently, 791 active trials are examining the potential of Desipramine Hydrochloride to mitigate Anorexia Nervosa, Irritable Bowel Syndrome (IBS) and Depressive symptoms.

Condition

Clinical Trials

Trial Phases

Diabetic Neuropathy

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Panic Disorder

13 Actively Recruiting

Not Applicable

Anorexia Nervosa

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Chronic Pain

0 Actively Recruiting

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Bulimia Nervosa

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Neuralgia, Postherpetic

0 Actively Recruiting

Desipramine Hydrochloride Reviews: What are patients saying about Desipramine Hydrochloride?

5

Patient Review

1/6/2014

Desipramine Hydrochloride for Depression

After my car accident, I was dealing with some really intense pain from Fibromyalgia. This drug helped to reduce that pain by 80%, which made a world of difference.

5

Patient Review

2/23/2013

Desipramine Hydrochloride for Anxious

5

Patient Review

5/6/2013

Desipramine Hydrochloride for Neuropathic Pain

5

Patient Review

9/13/2022

Desipramine Hydrochloride for Panic Disorder

This treatment is really effective for people suffering from PTSD.

4.7

Patient Review

2/4/2014

Desipramine Hydrochloride for Depression

Dr. Ackerman prescribed this medication to help with my depression, and it's done wonders in restoring my quality of life.

3.7

Patient Review

2/23/2014

Desipramine Hydrochloride for Depression

Amongst the SSRIs and SNRIs I've tried, this one is most effective for with fewest side effects. The only complaint I have is that if I forget to take it, I become very energetic (manic?) the next morning and vomit shortly after lunch.

2.3

Patient Review

6/27/2020

Desipramine Hydrochloride for Depression

My psychiatrist had me start with 150 milligrams, and after only five days I had to go to the emergency room. I was in so much pain I could barely walk or eat, urinating was agony, and my heart raced just from walking up the stairs. If I didn't know him, I would have thought he was trying to kill me!

2.3

Patient Review

8/20/2014

Desipramine Hydrochloride for Neuropathic Pain

My depression has decreased since taking this medication, but I've noticed some memory loss or confusion. I'm also sleepier and have less energy than before.

1.3

Patient Review

8/4/2017

Desipramine Hydrochloride for Neuropathic Pain

I would not recommend this drug to anyone. I experienced terrible constipation and pelvic pain as a result of the 100 mg dosage. This medication did nothing to ease my neuropathic pain, and if anything made it worse.

1

Patient Review

2/3/2015

Desipramine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I took the recommended dosage of 50mg for pain relief, but unfortunately woke up in more pain than before. This might work better for other people, but I didn't have a great experience with it.

1

Patient Review

8/4/2017

Desipramine Hydrochloride for Neuropathic Pain

This medication was an complete nightmare for me. I developed such severe constipation that I ended up with a painful UTI, which then led to burning pain and pelvic cramps. Lowering my dosage did nothing to help ease these symptoms, so I would advise anyone thinking of taking this drug to steer clear.

1

Patient Review

3/10/2013

Desipramine Hydrochloride for Neuropathic Pain

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about desipramine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does desipramine cause weight gain?

"Desipramine (Norpramin) can cause weight gain, though some people have lost weight while taking the medication. If you have experienced a significant change in weight while taking desipramine (Norpramin), speak to your provider."

Answered by AI

What is desipramine hydrochloride used for?

"Desipramine is a medication used to treat depression that belongs to a class of medications called tricyclic antidepressants. These drugs work by increasing the levels of natural substances in the brain that are needed for mental balance."

Answered by AI

How does desipramine make you feel?

"If you experience any of the following effects for an extended period of time, or if they worsen, notify your doctor or pharmacist. These effects include: headache, nausea, dizziness, drowsiness, nervousness, trouble sleeping, blurred vision, increased appetite, weight gain, constipation, and dry mouth."

Answered by AI

Is desipramine used for pain?

"Desipramine is a type of antidepressant medication known as a tricyclic antidepressant (TCA). It is sometimes used to treat chronic neuropathic pain (pain due to nerve damage or changes in the central nervous system (CNS))."

Answered by AI

Clinical Trials for Desipramine Hydrochloride

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Desipramine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Desipramine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Have you considered Desipramine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Desipramine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Desipramine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Desipramine Hydrochloride, we think they might fit your search criteria.
Go to Trials